Clinical Trials
4 trialsNCT07625644 2026-06-04
Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer
SystImmune Inc.
Phase 3 Not yet recruiting
NCT02688036 2026-05-29
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Completed
NCT07328490 2026-04-28
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed